News Summary

Montréal-based biotech startup Avitia has partnered with Genoscience, a private health clinic, to expand access to their non-invasive liquid biopsy tests across Quebec. This collaboration aims to provide cancer diagnostic services to patients outside of major urban centers, reducing the strain on hospital infrastructure. Avitia’s technology, which uses next-generation sequencing to detect cancer mutations, has already been employed in over 40,000 diagnostic tests. The company is also working to enhance its informatics platform and develop specific products for diagnosing endometrial and uterine cancers. Avitia’s growth plan includes launching international partnerships in the Middle East and Southeast Asia.